Julian S. Gangolli
CIK: 0001532023
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Sep 14, 2026KRYS
Krystal Biotech, Inc.
Award(A)DirectStock Option (Right to Buy)
1.2K shares- - Sep 14, 2026KRYS
Krystal Biotech, Inc.
Award(A)DirectRestricted Stock Units
471 shares- - Oct 1, 2025OTLK
Outlook Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
286.7K shares- - Jun 30, 2025KRYS
Krystal Biotech, Inc.
Award(A)DirectStock Option (Right to Buy)
5K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
Disposition(D)Direct15K shares- - Feb 4, 2025RVNC
Revance Therapeutics, Inc.
Tender Offer(U)Direct30.1K shares at avg. $3.65$110K - Oct 1, 2024OTLK
Outlook Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
71.2K shares- - Oct 1, 2024OTLK
Outlook Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
56.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  KRYS Krystal Biotech, Inc. | Award(A) Stock Option (Right to Buy) | 1,187 | - | - | Direct |
| Sep 14, 2026 | KRYS Krystal Biotech, Inc. | Award(A) Restricted Stock Units | 471 | - | - | Direct |
| Oct 1, 2025 |  OTLK Outlook Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 286,734 | - | - | Direct |
| Jun 30, 2025 | KRYS Krystal Biotech, Inc. | Award(A) Stock Option (Right to Buy) | 5,000 | - | - | Direct |
| Feb 6, 2025 |  RVNC Revance Therapeutics, Inc. | Disposition(D) | 15,000 | - | - | Direct |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | Tender Offer(U) | 30,106 | $3.65 | $109,887 | Direct |
| Oct 1, 2024 | OTLK Outlook Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 71,169 | - | - | Direct |
| Oct 1, 2024 | OTLK Outlook Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 56,636 | - | - | Direct |
1-8 of 8 transactions
About Gangolli Julian S
Gangolli Julian S (SEC CIK 0001532023) files insider reports with the SEC as Director of Krystal Biotech, Inc. (KRYS), Director of Outlook Therapeutics, Inc. (OTLK) and Director of Revance Therapeutics, Inc. (RVNC).
Signal8 holds 5 ownership filings by Gangolli Julian S, all Form 4s, filed between Oct 3, 2024 and Sep 16, 2026. Those filings report 8 transactions, from Oct 1, 2024 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gangolli Julian S's filings is in PITTSBURGH, PA.
Recent filings by Gangolli Julian S
- Sep 14, 2026: Grants or awards of KRYS derivative securities (2 lines, Form 4, code A).
- Oct 1, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
- Jun 30, 2025: Grant or award of KRYS derivative securities (Form 4, code A).
- Feb 6, 2025: Disposition to issuer transaction of RVNC shares (Form 4, code D).
- Feb 4, 2025: Tender of shares transaction of RVNC shares (Form 4, code U).
Other insiders filing for Krystal Biotech, Inc. (KRYS)
- ROSSI DINO A, Director
- Sutherland Everett Rand, Director
- Mazzacco Catherine, Director
- Mason Christopher, Director
- JANNEY DANIEL, Director
- Krishnan Suma, President, R&D